Table 1.
Clinical and demographic characteristics at baseline.
| PD-NC N = 84 | PD-MCI N = 55 | Total N = 139 | p-value | |
|---|---|---|---|---|
| Men, n (%) | 52 (61.9) | 35 (63.6) | 87 (62.6) | 0.8 |
| Age, years | 64.4 ± 10.4 | 67.5 ± 7.4 | 65.7 ± 9.4 | 0.07 |
| Age at onset, years | 61.6 ± 11.0 | 64.5 ± 7.8 | 62.8 ± 10.0 | 0.09 |
| Education, years | 9.3 ± 4.4 | 8.3 ± 4.6 | 8.9 ± 4.6 | 0.2 |
| UPDRS-ME score | 25.4 ± 14.5 | 27.4 ± 11.9 | 26.2 ± 13.5 | 0.4 |
| HY stage | 1.9 ± 0.6 | 2.2 ± 0.7 | 2.0 ± 0.7 | 0.02 |
| Disease duration, years | 3.0 ± 2.9 | 3.0 ± 2.7 | 3.0 ± 2.8 | 0.9 |
| Depression, n (%) | 29 (34.5) | 22 (40.0) | 51 (36.7) | 0.4 |
| LED mg/day | 437.2 ± 463.8 | 397.9 ± 408.8 | 421.8 ± 442.0 | 0.6 |
| Phenotype (%) | ||||
| TD | 32 (38.1) | 11 (20.0) | 43 (30.9) | / |
| PIGD | 47 (55.9) | 39 (70.9) | 86 (61.9) | / |
| Mixed | 5 (5.9) | 5 (9.1) | 10 (7.2) | 0.07 |
PD: Parkinson’s Disease; PD-NC: PD with Normal Cognition; PD-MCI: PD with Mild Cognitive Impairment; UPDRS-ME: Unified Parkinson’s Disease Rating Scale Motor Examination; HY: Hoehn and Yahr; LED: Levodopa Equivalent Daily Dose; TD: Tremor Dominant; PIGD: Postural Instability Gait Difficulty.